Diagnostic utility of p53, SMAD4, and the novel biomarker PON2 in FNA of pancreatic ductal adenocarcinoma
Combined p53 and SMAD4 immunostaining could help improve FNA diagnosis of PDACs, particularly in challenging cases. PON2 is differentially expressed in PDAC cases and may serve as a potential biomarker, warranting further investigation.
Authors
- Guoping Cai (ORCID: https://orcid.org/0000-0002-8725-5940)
- Maria C. Olave (ORCID: https://orcid.org/0000-0001-5109-907X)
- Ruimeng Yang (ORCID: https://orcid.org/0000-0003-2768-9429)
- Esther Yoon (ORCID: https://orcid.org/0000-0001-9378-3988)
- Catherine Gereg
Institutions
- Yale Cancer Center (US)
- Yale University (US)
Publication Details
- Journal
- Cancer Cytopathology
- Published
- 2025-10-29
- DOI
- https://doi.org/10.1002/cncy.70058
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Yale University